BioCentury | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

...by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals...
...and fluorescein angiography, and best corrected visual acuity (BCVA) Status: Phase I/II data Milestone: NA Sandi Wong RXI-109 RXi Pharmaceuticals...
BioCentury | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

...terms. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass. Iovance Biotherapeutics (NASDAQ:IOVA), San Carlos, Calif. Business: Cancer Shannon Lehnbeuter Iovance Biotherapeutics RXi Pharmaceuticals...
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Canbridge's U.S. office in Cambridge, Mass. He was CFO of Pfenex Inc. (NYSE-M:PFNX). RNAi company RXi Pharmaceuticals...
BioCentury | Jul 5, 2017
Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

...year end. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals...
...and changes in best corrected visual acuity (BCVA) Status: Completed Phase I/II enrollment Milestone: NA Meghan Sullivan RXI-109 RXi Pharmaceuticals...
BioCentury | May 26, 2017
Company News

PCI, RXi extend preclinical collaboration

...PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and...
...OSE:PCIB), Oslo, Norway RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Business: Cancer, Drug delivery Julian Zhu PCI Biotech Holding ASA RXi Pharmaceuticals...
BioCentury | Jan 6, 2017
Finance

Good riddance

...$74.9 $1,068.9 $1,133.7 6% RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 12/21/16 $24.4 $170.5 $174.0 2% RXi Pharmaceuticals...
BioCentury | Dec 21, 2016
Financial News

RXi completes follow-on

...convertible into 1,111 shares of common stock and 1,111 warrants. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass. Alex Himes RXi Pharmaceuticals...
BioCentury | Nov 15, 2016
Financial News

RXi amends follow-on

...into 840 common shares, and warrants to purchase 420 shares. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Alicia Parker RXi Pharmaceuticals...
BioCentury | Oct 31, 2016
Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Business: Gene/Cell therapy, Dermatology, Ophthalmic Date announced: 2016-10-21 Type: Follow-on To be raised: Up to $20.7 million Units: TBD Price Prior: $1.19 Underwriter: Ladenburg Thalmann Note: Each class A...
BioCentury | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

...respond in time for publication (see BioCentury, May 4, 2015). MirImmune Inc. , Cambridge, Mass. RXi Pharmaceuticals...
Items per page:
1 - 10 of 114
BioCentury | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

...by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals...
...and fluorescein angiography, and best corrected visual acuity (BCVA) Status: Phase I/II data Milestone: NA Sandi Wong RXI-109 RXi Pharmaceuticals...
BioCentury | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

...terms. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass. Iovance Biotherapeutics (NASDAQ:IOVA), San Carlos, Calif. Business: Cancer Shannon Lehnbeuter Iovance Biotherapeutics RXi Pharmaceuticals...
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Canbridge's U.S. office in Cambridge, Mass. He was CFO of Pfenex Inc. (NYSE-M:PFNX). RNAi company RXi Pharmaceuticals...
BioCentury | Jul 5, 2017
Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

...year end. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals...
...and changes in best corrected visual acuity (BCVA) Status: Completed Phase I/II enrollment Milestone: NA Meghan Sullivan RXI-109 RXi Pharmaceuticals...
BioCentury | May 26, 2017
Company News

PCI, RXi extend preclinical collaboration

...PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and...
...OSE:PCIB), Oslo, Norway RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Business: Cancer, Drug delivery Julian Zhu PCI Biotech Holding ASA RXi Pharmaceuticals...
BioCentury | Jan 6, 2017
Finance

Good riddance

...$74.9 $1,068.9 $1,133.7 6% RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 12/21/16 $24.4 $170.5 $174.0 2% RXi Pharmaceuticals...
BioCentury | Dec 21, 2016
Financial News

RXi completes follow-on

...convertible into 1,111 shares of common stock and 1,111 warrants. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass. Alex Himes RXi Pharmaceuticals...
BioCentury | Nov 15, 2016
Financial News

RXi amends follow-on

...into 840 common shares, and warrants to purchase 420 shares. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Alicia Parker RXi Pharmaceuticals...
BioCentury | Oct 31, 2016
Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Business: Gene/Cell therapy, Dermatology, Ophthalmic Date announced: 2016-10-21 Type: Follow-on To be raised: Up to $20.7 million Units: TBD Price Prior: $1.19 Underwriter: Ladenburg Thalmann Note: Each class A...
BioCentury | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

...respond in time for publication (see BioCentury, May 4, 2015). MirImmune Inc. , Cambridge, Mass. RXi Pharmaceuticals...
Items per page:
1 - 10 of 114